Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.52
(
-0.87%
)
Bitcoin
70,585.98
(
0.98%
)
News Focus
News Focus

Replies to post #193963 on Biotech Values

Replies to #193963 on Biotech Values
icon url

DewDiligence

07/31/15 11:02 AM

#193972 RE: lgonber #193963

OXGN—To reiterate, I haven’t followed the company closely for several years. However, I do disagree with your contention that fosbretabulin (f/k/a CA4P) has a benign side-effect profile. Also, I would question any notion that the planned phase-3 trial in ovarian cancer is “lay down.” Regards, Dew
icon url

DewDiligence

09/29/15 7:52 PM

#195457 RE: lgonber #193963

OXGN—They are setting up a “laydown” PIII SPA for first chemo-free treatment of ovarian cancer.

Inasmuch as the phase-2/3 ovarian trial described in #msg-117348101 has a different design than the trial you referred to in your post (i.e. both arms in the new trial include chemo), I presume that the SPA you anticipated is now off the table.